Background: Cytarabine (CA) is used to treat dogs with meningoencephalomyelitis of unknown etiology (MUE) by subcutaneous (SC) or intravenous (IV) administration.
Aim: The objective was to investigate transdermal iontophoresis and rectal administration as alternative routes of CA delivery.
Methods: Two client-owned dogs with MUE were studied. The ActivaPatch® IONTOGO 12.0 iontophoresis drug delivery system delivered 200 mg/m^2 CA transdermally. Blood samples were collected by sparse sampling technique after initiation of the device. At another visit, 100 mg/m^2 CA was administered rectally. Blood samples were collected by sparse sampling technique after administration. Plasma CA concentrations were measured by high-pressure liquid chromatography (HPLC).
Results: The concentration of plasma CA after transdermal and rectal administration was below the limits of quantification (0.1ug/mL) in all samples suggesting inadequate bioavailability with transdermal and rectal administration.
Conclusion: Transdermal and rectal CA administration are not reasonable alternative routes of delivery.
The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
We use cookies and other tracking technologies to work properly, to analyze our website traffic, and to understand where our visitors are coming from. More InfoGot It!
